Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
2.800
-0.040 (-1.41%)
Aug 29, 2025, 4:00 PM - Market closed
Jasper Therapeutics Employees
Jasper Therapeutics had 64 employees as of December 31, 2024. The number of employees increased by 19 or 42.22% compared to the previous year.
Employees
64
Change (1Y)
19
Growth (1Y)
42.22%
Revenue / Employee
n/a
Profits / Employee
-$1,420,656
Market Cap
45.51M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64 | 19 | 42.22% |
| Dec 31, 2023 | 45 | 10 | 28.57% |
| Dec 31, 2022 | 35 | 10 | 40.00% |
| Dec 31, 2021 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
JSPR News
- 4 days ago - Jasper Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 7 weeks ago - Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway - GlobeNewsWire
- 7 weeks ago - Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem - Benzinga
- 7 weeks ago - Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria - GlobeNewsWire
- 2 months ago - Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - GlobeNewsWire
- 3 months ago - Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress - GlobeNewsWire